indicate that type I and type II NFI GRD protein possess the same ability to stimulate ras p21GTPase activity in vitro.
In addition, GAP activities of two types of NFI proteins may be differentially regulated by lipids such as AA. It has been demonstrated that the activation of the ras oncogene product by point mutation is a rare event in gastric cancers (i) .
However, since ras p21 has been shown to play a crucial role in cellular proliferation and malignant transformation in a number of other cell types (17) , an alteration in the ras-related signalling pathway might be involved in gastric tumorigenesis. The present results, therefore, suggest that differential expression of two types of NFI-GRD in cancer cells might affect the ras-related signal transduction through different regulation of both types of NFI-GRD by AA. Alternatively, either an insertion (type II) or a deletion (type I) of 21 amino acids may change the whole NFI protein structure then altering its GAP activity for ras p21, but it may not affect the GAP activity of bacterially expressed NFI-GRD The biochemical abnormalities detected in humans affected by hepatorenal tyrosinemia type I include increases of plasma concentrations of tyrosine and methionine to several fold of normal (6) . However, the diagnostic hallmarks of the condition have been elevations of succinylacetone in both blood and urine (7). This substance is a highly toxic compound and its accumulation is thought to explain the hepatorenal cellular damage associated with tyrosinemia (8) . The question has been debated as to a possible prenatal onset of symptoms in human hepatorenal tyrosinemia since an increase of serum a-fetoprotein up to 1000-fold was noted and affected individuals become sick in the early post-natal period (9) . However, this would present an exception to the majority of disorders of amino acid metabolism in which transfer of amino acids across the placenta and correction by the normal enzyme levels in the heterozygous mother succeed in maintaining homeostasis until birth.
Since the deletion homozygous mice that lack the FAH gene seemed to offer a potential model of human hepatorenal tyrosinemia, they provided an opportunity to determine the time of perinatal onset of metabolic abnormalities in this disease, and were, therefore, subjected to the appropriate tests. Even though ultrastructural abnormalities of hepatocytes characterize these deletion homozygotes before birth (i0), no metabolic abnormalities could be detected prenatally. These results suggest strongly that the previously described abnormalities of lethal albino deletion homozygotes (4) are caused by the absence of genes other than that encoding FAH.
EXPERIMENTAL PROCEDURES Animals
Mice heterozygous for the lethal albino deletion c 3H were bred to 3H 3H 3H ch newborn albino homozygotes (c /c ), heterozygotes (c /c ) and homozygous normal littermates (cCh/c ch) distinguishable by skin and eye pigmentation (albino, light, dark). In order to obtain fetuses for prenatal studies, matings were timed by the observation of vaginal plugs, fetuses were dissected and thei~ genotypes identified by eye pigmentation. Since deletion homozygotes (c H/c3H) die within a few hours after birth, the majority of newborn mice were dissected as soon as possible. In order to maximize accumulation of possible metabolites, some newborn homozygotes were sustained with glucose injections, monitored and dissected between 3-6 1/2 hours later. The remaining newborn c3H/c 3H homozygotes and their normal littermates were injected after birth intraperitoneally with a combination of N 6, O2-dibutyryladenosine 3', 5'-cyclic monophosphate (cAMP, i00 mg/kg of body weight) and dexamethasone (dex, I00 #g/kg of body weight) in 0.85% saline for possible induction of liver specific enzymes, or with 0.85% saline alone for control.
Livers were removed from albino deletion homozygous and pigmented normal littermates 2 hr after injection.
Blood was obtained by decapitation and collected in capillary tubes.
Subsequently, plasma was pooled from identical genotypes of multiple litters. All specimens were stored at -70°C until analysis.
Determinations of Amino Acids
Plasma samples (2 #i) were qualitatively screened by one dimensional thin layer chromatography for the presence of excess tyrosine and methionine (ii) .
For
The sample was injected into a Beckman II9-CL amino acid analyzer.
Determinations of Liver Succinylacetone
Five drops of 2N HCI and 25 #i of internal standard (1.4 mg/ml malonic acid) were added to the mouse livers which were homogenized in methanol.
The sample was centrifuged for I0 min, the supernatant transferred to a conical tube and taken to dryness under a stream of air.
The TMS (trimethylsilyl) derivative was prepared by the addition of 50 #i of BSTFA (N,0-bis trimethylsilyl) trifluoroacetamide/l% TMCS (trimethyl chlorosilene).
The sample was heated for 15-20 min at 60°C and a 3 #i aliquot was injected onto a 60 m SPB-I GC column.
An HP 5995B mass spectrometer was used as the detector with selected-ion-monitoring at m/z 157, 169, 185, 233, 243, 287 and 302 which served to identify succinylacetone and the internal standard (m/z 233).
In addition, ions 179 and 308 indicative of 4-hydroxyphenyllactic acid were monitored. The detection limit for succinylacetone under these conditions was I0 #g.
Since pooled liver samples were extracted and the extract taken up in a small volume, the amount of succinylacetone detectable on a wet weight basis varied with the amount of liver extracted.
RESULTS AND DISCUSSION
Initially, plasma amino acid levels were determined for newborn mice homozygous for the c 3H deletion and their control littermates as described in Experimental Procedures.
Visual inspection of the thin layer plate in a preliminary experiment suggested that mutant newborns had abnormally high plasma tyrosine concentrations, but no other apparent amino acid abnormalities. Plasma was then pooled separately from 19 deletion homozygous, 28 heterozygous and 24 wild type homozygous newborn mice for one set of determinations and from 15, 16, and 8 mice of the respective genotypes for a second set. As shown in Table ] , the deletion homozygous newborn mice had concentrations of methionine 1.4 times, and tyrosine 1.8
times as high as their normal littermates, both heterozygous and homozygous.
In view of the mild metabolic abnormalities detected in the newborn period, the next step addressed the question if the toxic metabolite, succinylacetone, could be identified before birth. Liver organic acid On the other hand, 4-hydroxy phenyllactic acid was present but not related to particular genotypes (Table 2) . Additional analyses of livers of eight separate sets of newborn mice representing all three genotypes also failed to show any detectable succinylacetone ( Table 2 ).
The mutant mouse strain used in these studies is one of a group of strains carrying different overlapping deletions at and around the albino locus on Nevertheless, hypoglycemia resulting from the absence of normal postnatal (Table 2) suggests that the pathway for tyrosine metabolism is developing in the perinatal period, comparable to observations of premature human infants. Even though mildly elevated levels of methionine and tyrosine were detected in the plasma of deletion homozygous mice, the toxic metabolite succinylacetone was not found either pre-or post-natally in the liver within the time period of study.
The early lethality of the mice homozygous for the chromosomal deletions contrasts with the human disorder of hepatorenal tyrosinemia where long survival has been noted frequently. This difference might, of course, merely reflect other differences between the intermediary metabolism of mice and humans, as observed in several other murine models in which a particular homologous mutation causes phenotypes quite different from those described in humans (15) . However, in the case of the FAH deficient mice, the early lethality appears to be more easily explained by the inclusion in the chromosomal deletions, measuring more than 1.5 cM, of many genes in contrast to the single gene mutation that causes the human tyrosinemia I. Even though the normal gene product of FAH might conceivably function as a transacting regulatory factor in addition to encoding an enzyme of intermediary metabolism, it does not appear that the defects identified prenatally in fetuses homozygous for the lethal albino deletions (i0) are caused by early effects of tyrosinemia.
